

Consolidated Financial Result Digest FY2026/3 2Q

(Fiscal Year Ended March 31, 2026)

Taiyo Holdings Co., Ltd.
(4626: Prime Market of Tokyo Stock Exchange)
Nov. 6, 2025




Any information incorporated in this document is not intended for suggestion of purchase or sale of equity share of the company. All the description and projection are based on the company's own analysis at the time of compilation, and their accuracy is not guaranteed. These data may be revised without prior announcement. The company will neither assume nor compensate any loss of anybody resulting from decision based on information provided here.

Our Business Segments

Electronics

Developing, manufacturing, purchasing and selling chemicals that used in printed circuit boards (PCB) and other electronic components



Medical and Pharmaceuticals

Manufacturing and marketing ethical pharmaceuticals, contract development and manufacturing organization (CDMO), manufacturing and selling dental prosthetics



ICT and Sustainability

Businesses included ICT, fine chemicals, energy, and food, etc.



FY2026/3 2Q Overview

Electronics

- Net sales increased by 9% year on year on a cumulative basis and by 8% quarter on quarter

<Reasons related to cumulative YoY>

While the yen appreciated, sales volume of PKG and rigid products increased.

PKG products: + Sales volume increased due to stronger demand mainly for memory products.

Rigid products: + Sales volume increased, mainly for automotive and smartphone products.

− Sales volume for display (white dry film) products decreased.

Foreign exchange − The appreciation of the yen had a negative impact on business results.

Effects:

Average exchange rate during the second quarter:

<FY2025/3> 152.3 JPY/USD <FY2026/3> 146.5 JPY/USD

<Reasons related to QoQ>

Sales volume increased, mainly for PKG products.

Medical and Pharmaceuticals

- Net sales increased by 22% year on year

<Reasons related to cumulative YoY>

Contract manufacturing business saw an increase in contract volume.

Contract manufacturing + Contract volume from exiting customers increased.

business: + The start of full-scale contract manufacturing for new customers resulted in an increase in contract volume.

Manufacturing and + Sale volume increased due to higher demand in line with supply shortages of drugs with the same indications at other companies as well as an increase in supply volume of cough suppressants.

marketing business:

− Sales volume decreased for items subject to the elective care scheme, which was implemented from October 2024.

Company

- Revised upward the full-year forecast for the fiscal year ended March 31, 2026 (FY 2026/3)
- Decided to increase the interim dividend for FY2026/3
- Formulated a Medium-term Management Plan
- Decided to implement a stock split effective December 1, 2025

Consolidated Financial Results Summary

	①	②	②-①	(②-①)/①	③	②/③	④	②/④
Unit : JPY Million	2025/3 1 st Half Result	2026/3 1 st Half Result	YoY	% of Changes	2026/3 1 st Half Forecast (Announced on Aug. 1)	% of Progress	2026/3 Full Year Forecast (Announced on Aug. 1)	% of Progress
Net Sales	59,899	67,830	7,930	13%	64,800	105%	125,700	54%
Operating Income	12,430	15,187	2,756	22%	13,200	115%	24,700	61%
Ordinary Income	12,418	15,078	2,659	21%	12,700	119%	23,700	64%
Net Income	9,209	11,022	1,812	20%	8,900	124%	16,000	69%
Exchange rate of JPY/USD	152.3	146.5	(5.8)		*1		*2	
EBITDA	16,986	19,477	2,491	15%	17,400	112%	33,300	58%
Operating Income Margin	21%	22%			20%		20%	
EBITDA Margin	28%	29%			27%		26%	

*1 1Q (actual results) : 145.2 JPY/USD 2Q (forecast announced at the beginning of 2026/3) : 145.0 JPY/USD

*2 1Q (actual results) : 145.2 JPY/USD 2Q to 4Q (forecast announced at the beginning of 2026/3) : 145.0 JPY/USD

Performance by Segment


Cumulative Net Sales, Operating Income and EBITDA

		①	②	②-①	(②-①)/①	③	②/③	④	②/④
Unit : JPY Million		2025/3 1 st -Half Result	2026/3 1 st -Half Result	YoY	% of Changes	2026/3 1 st -Half Forecast (Announced on Aug. 1)	% of Progress	2026/3 Full-Year Forecast (Announced on Aug. 1)	% of Progress
Electronics	Net Sales	42,567	46,346	3,779	9%	43,200	107%	83,800	55%
	Operating Income	12,045	13,794	1,749	15%	11,500	120%	21,500	64%
	Operating Income Margin	28%	30%			27%		26%	
	EBITDA	13,772	15,616	1,844	13%	13,200	118%	25,200	62%
	EBITDA Margin	32%	34%			31%		30%	
Medical and Pharmaceuticals	Net Sales	15,078	18,451	3,373	22%	18,500	100%	35,400	52%
	Operating Income	931	2,426	1,495	161%	2,700	90%	4,600	53%
	Operating Income margin	6%	13%			15%		13%	
	EBITDA	3,296	4,387	1,090	33%	4,600	95%	8,600	51%
	EBITDA Margin	22%	24%			25%		24%	
ICT and Sustainability	Net Sales	2,254	3,031	777	35%	-	-	-	-
	Operating Income	138	18	(120)	(87%)	-	-	-	-
	Operating Income Margin	6%	1%			-	-	-	-
Company Expense	Operating Income / Loss	(685)	(1,052)	(367)		-	-	-	-

Trend of Quarterly Performance

Net Sales and Operating Income

Unit : JPY Million



BS- Comparison with the Previous Term

Unit : JPY Million

	2025/3	2025/9	Changes		2025/3	2025/9	Changes
Cash and Deposits	44,903	39,307	(5,595)	Notes and Account Payable	8,505	10,200	1,695
Accounts Receivables* ¹	27,896	34,752	6,855	Short Term Borrowings* ³	17,634	15,338	(2,295)
Inventory* ²	21,345	21,335	(9)	Long Term Borrowings	46,888	43,308	(3,580)
Others	3,862	3,318	(544)	Others	16,015	15,724	(291)
Total Current Assets	98,008	98,713	705	Total Liabilities	89,043	84,571	(4,472)
Tangible Fixed Assets	67,638	67,116	(522)	Shareholders Equity	94,011	97,845	3,833
Intangible Fixed Assets	16,341	15,395	(945)	Accumulated Other Comprehensive Income	8,962	9,162	200
Investments and Other Assets	10,034	10,359	324	Non-Controlling Interest	4	5	1
Total Fixed Assets	94,014	92,871	(1,143)	Total Net Assets	102,978	107,013	4,034
Total Assets	192,022	191,585	(437)	Total Liabilities and Net Assets	192,022	191,585	(437)
				Equity to Asset Ratio	53.6%	55.9%	2.2%

*1 Accounts Receivables : Notes Receivable + Accounts Receivable-Trade + Contract Asset

*2 Inventories : Merchandise and Finished Goods + Work in Process + Raw Materials and Supplies

*3 Short-Term Borrowings : Short-Term Borrowings + Long-Term Borrowings Scheduled to Be Repaid within One Year

Revised Forecast for the Fiscal Year Ended March 31, 2026 (FY 2026/3)

- ✓ We have revised the full-year forecast for FY 2026/3. The reasons for revision are as follows.
- Results for Electronics business are expected to exceed the forecasts announced on August 1, 2025.
 - We recorded extraordinary income due to the liquidation of our consolidated subsidiary and non-operating income due to the partial sale of CVC fund.

Unit : JPY Million		2026/3 Full-Year Forecast (Announced on Aug. 1) ^{*1}		2026/3 Full-Year Forecast (Announced on Nov. 6) ^{*2}		Change Ratio	
		Amount	Profit ratio	Amount	Profit ratio	Amount	Ratio
Consolidated	Net Sales	125,700		128,800		+3,100	+2%
	Operating Income	24,700	20%	26,900	21%	+2,200	+9%
	Ordinary Income	23,700	19%	26,500	21%	+2,800	+12%
	Net Income	16,000	13%	18,400	14%	+2,400	+15%
	EBITDA	33,300	26%	35,500	28%	+2,200	+7%
Electronics	Net Sales	83,800		86,900		+3,100	+4%
	Operating Income	21,500	26%	23,700	27%	+2,200	+10%
	EBITDA	25,200	30%	27,400	32%	+2,200	+9%
Medical and Pharmaceuticals	Net Sales	35,400		35,400		-	-
	Operating Income	4,600	13%	4,600	13%	-	-
	EBITDA	8,600	24%	8,600	24%	-	-

*1 1Q (actual results) : 145.2 JPY/USD 2Q to 4Q forecast (announced at the beginning of 2025/3) : 145.0 JPY/USD

*2 Revised by replacing the 1st half quarter forecasts of Electronics business with the actual results (146.5 JPY/USD) and remaining the 2nd half quarter forecast (145.0 JPY/USD) unchanged from that disclosed on August 1, 2025.

Shareholder Returns

- ✓ We have decided to increase the interim dividend per share for the fiscal year ended March 31, 2026, by 20.00 yen. As for the fiscal year-end dividend, we will continue to consider flexible and responsive measures based on our shareholder returns policy, which targets a consolidated total payout ratio of 100%, depending on performance.


Dividend per share

Reference date	2nd quarter-end	Fiscal year-end	Total
Previous forecast (announced on April 30, 2025)	145.00 yen	145.00 yen	290.00 yen
Current term results (fiscal year ended March 31, 2026)	up by 20 yen 165.00 yen	—	—
Previous term results (fiscal year ended March 31, 2025)	40.00 yen	150.00 yen	190.00 yen

Financial Targets Under Medium-term Management Plan

- ✓ We have established new financial targets toward realizing its long-term management plan for 2030 and enhancing corporate value. We have also formulated a Medium-term Management Plan as the roadmap to achieve these targets.

Financial Targets for the fiscal year ending March 31, 2031 (FY2031/3)



Unit: JPY Billion		FY2025/3 (actual)		FY2031/3 (target)	
		Amounts	Profit margin	Amounts	Profit margin
Consolidated	Net sales	119.0	—	180.0	—
	Operating Income	22.0	19%	47.0	26%
	EBITDA	31.7	27%	58.0	32%
Electronics	Net sales	81.7	—	128.0	—
	Operating Income	21.4	26%	39.0	30%
	EBITDA	25.1	31%	44.0	34%
Medical & Pharmaceuticals	Net sales	31.5	—	43.0	—
	Operating Income	2.0	6%	9.0	21%
	EBITDA	7.0	22%	13.0	30%

*Please refer to the "[Notice Regarding the Formulation of the Medium-term Management Plan](#)" disclosed on August 28 2025, for details.

Stock Split

- ✓ We will conduct a stock split to make its shares more accessible to investors and expand its retail investor base by lowering the price per investment unit.

Stock split ratio*1

Conduct a two-for-one split of each share of common stock held by shareholders listed or recorded in the shareholder registry as of the record date.

Split ratio

1 : 2

Record date

November 30, 2025

Reference date

December 1, 2025

Dividends on shares held

Fiscal year-end dividend per share practically remains unchanged.

Before the split

145.00 yen/share

After the split

72.50 yen/share + 72.50 yen/share

Minimum investment amount for the shares

Reduced investment burden for investors, including retail investors

Before the split

Approx. 800,000 yen/100 shares*2

After the split

Approx. 400,000 yen/
100 shares

*1 Upon the implementation of the stock split, we will change the total number of shares authorized to be issued set forth in Article 6 of our Articles of Incorporation, with December 1, 2025 as the effective date.

*2 The investment amount per investment unit of 100 shares is calculated using the closing price of 8,080 yen/share on September 30, 2025 as the reference price.



Electronics

Electronics Terminology


Term	Definition
PCB	<u>P</u> rinted <u>C</u> ircuit <u>B</u> oard
SR	<u>S</u> older <u>R</u> esist, also known as Solder Mask
PKG	Semiconductor <u>P</u> ack <u>a</u> ge
DF	<u>D</u> ry <u>F</u> ilm
BU	<u>B</u> uild- <u>u</u> p

Electronics Product Classification

Group	Category		Type	Remarks
PCB insulating materials	Rigid	Regular	Liquid	▪ SR materials for insulation and surface protection use ▪ Marking, etching and plating materials ▪ Electronic materials etc.
		High end	Liquid／DF	
	PKG		Liquid／DF	
	FPC (Flexible printed circuit board)		Liquid／DF	
	BU		Liquid／DF	▪ Build-up materials for interlayer insulation and hole plugging use
Other related products	Others		Liquid／DF	▪ Conductive paste etc.


Electronics Net Sales by Product Category

Unit : JPY Million



Electronics Net Sales by Sales Area

Unit : JPY Million





Medical and Pharmaceuticals


Medical and Pharmaceutical Terminology

Term	Definition
LLP	<u>L</u> ong <u>L</u> isted <u>P</u> roduct A drug for which the patent or re-examination period has expired, enabling the sale of generic drugs
CDMO	<u>C</u> ontract <u>D</u> evelopment <u>M</u> anufacturing <u>O</u> rganization Organizations contracted to manufacture and develop pharmaceutical formulations
GMP	<u>G</u> ood <u>M</u> anufacturing <u>P</u> ractice Standards for manufacturing control and quality of pharmaceuticals and quasi-drugs

Medical and Pharmaceuticals Net Sales by Company

Unit : JPY Million

2Q Cumulative
YoY **QoQ**





Company

Taiyo Ink Mfg. Has Received Good Design Award

- ✓ “Inspiration Space,” the showroom area at Taiyo Ink Mfg.’s technology development center “InnoValley,” has been selected for the Good Design Award 2025*.
- ✓ This marks our second Good Design Award, following “T-LINKS,” Taiyo Pharma Tech’s employee welfare facility, in 2023.

Overview of Inspiration Space

An experiential showroom designed to deepen understanding of products in our Electronics Business. We aim to enable customers, developers, and other visitors to experience the connection between products and technology by combining digital and analog presentations to convey our technology, history, and future.



History Corner



Technology Corner



Future Corner

- “Inspiration Space” Introductory Video:

https://www.artfreak.co.jp/wscd/wp-content/uploads/2024/06/InspirationSpace_movie_low_0722.mp4

*The Good Design Award (organized by the Japan Institute of Design Promotion) is one of Japan’s leading design awards that was established in 1957 for the purpose of enriching people’s lives and society through design.

